Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical).


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
01 2023
Historique:
received: 11 03 2022
revised: 07 07 2022
pubmed: 15 7 2022
medline: 7 1 2023
entrez: 14 7 2022
Statut: ppublish

Résumé

Our objective was to provide consensus recommendations from a consortium of academic and industry experts in the field of lymphoma and imaging for consistent application of the Lugano classification.

Identifiants

pubmed: 35835580
pii: jnumed.122.264106
doi: 10.2967/jnumed.122.264106
pmc: PMC9841255
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102-108

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Department of Health
ID : RP-2-16-07-001
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT203148/Z/16/Z
Pays : United Kingdom

Informations de copyright

© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Références

Br J Cancer. 2013 Jul 23;109(2):312-7
pubmed: 23807169
Br J Haematol. 2021 Feb;192(3):504-513
pubmed: 32621535
Ann Oncol. 2013 Aug;24(8):2108-12
pubmed: 23585513
J Nucl Med. 2010 Jan;51(1):25-30
pubmed: 20009002
Radiology. 2016 Apr;279(1):306-13
pubmed: 26509293
Ann Oncol. 2018 Sep 1;29(9):1926-1931
pubmed: 30010775
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
J Nucl Med. 2018 Apr;59(4):589-595
pubmed: 28864629
J Clin Oncol. 2019 Jul 10;37(20):1732-1741
pubmed: 31112475
Clin Nucl Med. 2009 Jun;34(6):355-8
pubmed: 19487844
Blood Adv. 2020 Apr 28;4(8):1589-1593
pubmed: 32298429
Ann Oncol. 2017 Jul 1;28(7):1436-1447
pubmed: 28379322
Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):42-49
pubmed: 27839910
J Clin Oncol. 2023 Jan 10;41(2):336-342
pubmed: 35787017
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2034-2041
pubmed: 28733763
Ann Nucl Med. 2019 Jul;33(7):449-458
pubmed: 30929200
J Clin Oncol. 2018 Feb 10;36(5):454-462
pubmed: 29360414
J Nucl Med. 2010 Dec;51(12):1857-62
pubmed: 21078789
Lancet Haematol. 2021 Jan;8(1):e80-e93
pubmed: 33357487
Mayo Clin Proc. 2020 Jan;95(1):157-163
pubmed: 31902411
Lancet Oncol. 2018 Nov;19(11):1530-1542
pubmed: 30309758
Lancet Haematol. 2021 Jan;8(1):e67-e79
pubmed: 33357485
Eur J Haematol. 2015 Jan;94(1):23-30
pubmed: 24520874
Curr Treat Options Oncol. 2016 May;17(5):24
pubmed: 27032646
Hematol Oncol. 2019 Apr;37(2):168-175
pubmed: 30734341
J Nucl Med. 2019 Aug;60(8):1096-1102
pubmed: 30954945
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood Adv. 2021 May 11;5(9):2375-2384
pubmed: 33944897
Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1633-42
pubmed: 20428863
J Clin Oncol. 2014 Nov 1;32(31):3506-12
pubmed: 25267745
Blood. 2016 Nov 24;128(21):2489-2496
pubmed: 27574190
AJR Am J Roentgenol. 2010 Aug;195(2):333-40
pubmed: 20651187
Clin Adv Hematol Oncol. 2019 Jun;17(6):352-359
pubmed: 31437139
Br J Haematol. 2017 Oct;179(2):242-245
pubmed: 28677889
J Clin Oncol. 2012 Dec 10;30(35):4317-22
pubmed: 23109699
J Clin Oncol. 2014 Sep 20;32(27):3048-58
pubmed: 25113771
J Clin Oncol. 2011 Aug 10;29(23):3194-200
pubmed: 21747087
Leuk Lymphoma. 2021 Apr;62(4):1010-1012
pubmed: 33275056
Ann Oncol. 2016 Jun;27(6):1095-1099
pubmed: 27002106
Blood. 2016 Mar 24;127(12):1531-8
pubmed: 26747247
N Engl J Med. 2016 Jun 23;374(25):2419-29
pubmed: 27332902
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):97-110
pubmed: 28411336
Ann Oncol. 2016 Apr;27(4):719-24
pubmed: 26787236
Blood Adv. 2019 Jan 22;3(2):187-197
pubmed: 30670535
Hematol Oncol. 2015 Dec;33(4):151-8
pubmed: 25407794
J Nucl Med. 2017 Apr;58(4):523-532
pubmed: 28232605
J Nucl Med. 2023 Feb;64(2):239-243
pubmed: 35835581
J Natl Compr Canc Netw. 2019 Jun 1;17(6):650-661
pubmed: 31200358
Haematologica. 2020 Jan;105(1):e33-e36
pubmed: 31371411

Auteurs

Fabien Ricard (F)

Relay Therapeutics, Cambridge, Massachusetts; fabienricardmd@gmail.com.

Bruce Cheson (B)

Lymphoma Research Foundation, New York, New York.

Sally Barrington (S)

King's College London and Guy's and St. Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, United Kingdom.

Judith Trotman (J)

Concord Repatriation General Hospital, University of Sydney, Concord, New South Wales, Australia.

Annette Schmid (A)

Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts.

Guenther Brueggenwerth (G)

Bayer AG, Berlin, Germany.

Gilles Salles (G)

Department of Medicine, Memorial Sloan Kettering Cancer Center and Weil Cornell Medicine, New York, New York.

Larry Schwartz (L)

Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, Columbia, New York.

Greg Goldmacher (G)

Merck and Co, Inc., Kenilworth, New Jersey.

Rudresh Jarecha (R)

Deciphera Pharmaceuticals LLC, Waltham, Massachusetts.

Jayant Narang (J)

Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts.

Florence Broussais (F)

LYSARC, Pierre Benite, France.

Paul Galette (P)

GSK, Collegeville, Pennsylvania.

Min Liu (M)

Autolus Therapeutics, London, United Kingdom.

Surabhi Bajpai (S)

Calyx International, Billerica, Massachusetts.

Eric Perlman (E)

Perlman Advisory Group LLC, Boynton Beach, Florida.

Julie Gillis (J)

Merigold LLC, Branford, Connecticut.

Ira Smalberg (I)

Saint John's Cancer Institute and Tower Imaging Medical Group, Sherman Oaks, California.

Pierre Terve (P)

KEOSYS Medical Imaging, Saint Herblain, France.

Gudrun Zahlmann (G)

Quantitative Imaging Biomarkers Alliance, Radiological Society of North America, Oak Brook, Illinois; and.

Ron Korn (R)

TGEN/City of Hope and Imaging Endpoints Core Lab, Scottsdale, Arizona.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH